MX2022016365A - Formulacion de alta concentracion de proteinas de union a antigeno de factor xii. - Google Patents

Formulacion de alta concentracion de proteinas de union a antigeno de factor xii.

Info

Publication number
MX2022016365A
MX2022016365A MX2022016365A MX2022016365A MX2022016365A MX 2022016365 A MX2022016365 A MX 2022016365A MX 2022016365 A MX2022016365 A MX 2022016365A MX 2022016365 A MX2022016365 A MX 2022016365A MX 2022016365 A MX2022016365 A MX 2022016365A
Authority
MX
Mexico
Prior art keywords
antigen binding
factor xii
formulation
high concentration
binding proteins
Prior art date
Application number
MX2022016365A
Other languages
English (en)
Spanish (es)
Inventor
Michael Johnston
Dianna Grace Goodall
Nathan Aaron Edwards
Original Assignee
CSL Innovation Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Innovation Pty Ltd filed Critical CSL Innovation Pty Ltd
Publication of MX2022016365A publication Critical patent/MX2022016365A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2022016365A 2020-07-03 2021-07-05 Formulacion de alta concentracion de proteinas de union a antigeno de factor xii. MX2022016365A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20184004 2020-07-03
PCT/AU2021/050714 WO2022000046A1 (en) 2020-07-03 2021-07-05 High concentration formulation of factor xii antigen binding proteins

Publications (1)

Publication Number Publication Date
MX2022016365A true MX2022016365A (es) 2023-01-30

Family

ID=71514949

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016365A MX2022016365A (es) 2020-07-03 2021-07-05 Formulacion de alta concentracion de proteinas de union a antigeno de factor xii.

Country Status (12)

Country Link
US (1) US20240277839A1 (enExample)
EP (1) EP4175669A4 (enExample)
JP (1) JP7880827B2 (enExample)
KR (1) KR20230035355A (enExample)
CN (1) CN116322764A (enExample)
AU (1) AU2021302684A1 (enExample)
BR (1) BR112022026482A2 (enExample)
CA (1) CA3183508A1 (enExample)
CL (1) CL2023000004A1 (enExample)
IL (1) IL298989A (enExample)
MX (1) MX2022016365A (enExample)
WO (1) WO2022000046A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4337257A1 (en) * 2021-05-12 2024-03-20 AnaptysBio, Inc. Antibody composition
US20250042984A1 (en) * 2021-12-20 2025-02-06 CSL Innovation Pty Ltd Protein formulations and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20250164T1 (hr) 2011-07-22 2025-04-11 Csl Behring Gmbh Inhibitorna monoklonska antitijela protiv faktora xii/xiia i njihove uporabe
JP5859148B2 (ja) * 2012-03-08 2016-02-10 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Aβ抗体製剤
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) * 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
EP3325516B1 (en) * 2015-07-21 2021-12-15 Takeda Pharmaceutical Company Limited A monoclonal antibody inhibitor of factor xiia
EP3433274A1 (en) * 2016-03-25 2019-01-30 Visterra, Inc. Formulation of antibody molecules to dengue virus
EP3440107A4 (en) * 2016-04-06 2020-02-19 CSL Limited METHOD FOR TREATING ATHEROSCLEROSIS
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
BR112019011900A2 (pt) 2016-12-23 2019-11-26 Serum Institute Of India Private Limited métodos melhorados para aumentar a produtividade de anticorpos na cultura de células de mamíferos e minimizar a agregação durante os processos downs-tream, processos de formulação, e formulações de anticorpos estáveis obtidas dos mesmos
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
EA202190056A1 (ru) * 2018-06-19 2021-05-28 Ридженерон Фармасьютикалз, Инк. АНТИТЕЛА ПРОТИВ ФАКТОРА XII/XIIa И ИХ ПРИМЕНЕНИЕ
US12134657B2 (en) 2018-11-28 2024-11-05 Oregon Health & Science University Therapeutic factor XII antibody
US20230390418A1 (en) * 2020-10-29 2023-12-07 Regenxbio Inc. Vectorized factor xii antibodies and administration thereof

Also Published As

Publication number Publication date
WO2022000046A1 (en) 2022-01-06
CA3183508A1 (en) 2022-01-06
KR20230035355A (ko) 2023-03-13
CL2023000004A1 (es) 2023-08-25
AU2021302684A1 (en) 2023-02-23
EP4175669A1 (en) 2023-05-10
BR112022026482A2 (pt) 2023-01-31
JP7880827B2 (ja) 2026-06-26
US20240277839A1 (en) 2024-08-22
EP4175669A4 (en) 2025-11-12
JP2023531315A (ja) 2023-07-21
CN116322764A (zh) 2023-06-23
IL298989A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
ES2569409T3 (es) Composiciones de anticuerpo anti-CTLA-4
EA200870538A1 (ru) Лиофилизированные композиции анти-egfr антител
EA201992377A1 (ru) Стабильная композиция антитела
RU2013137740A (ru) Жидкая композиция, содержащая антитело высокой концентрации
EA202193240A1 (ru) Стабилизированные составы, содержащие анти-angptl3 антитела
MX2024000901A (es) Composiciones y metodos para la degradacion selectiva de proteinas dise?adas por ingenieria.
EA201992613A1 (ru) Фармацевтическая композиция, содержащая конструкции на основе биспецифического антитела, обеспечивающая улучшенное хранение и введение
EA200970880A1 (ru) Стабильные композиции на основе антител
AR079836A1 (es) Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleuquina-6 (il-6r)
RU2011142184A (ru) Фармацевтический состав, содержащий молекулы антител с улучшенными свойствами
EP4233892A3 (en) Stable anti-ifnar1 formulation
EA201790989A1 (ru) Стабильный препарат раствора белка, содержащего анти-vegf антитело в высокой концентрации
CL2023000004A1 (es) Formulación en concentración alta de proteínas de unión a antígeno del factor xii
BRPI0514340A (pt) formulações de estabilização
MX2021007393A (es) Formulacion de solucion de proteinas que contiene una alta concentracion de un anticuerpo anti-vegf.
PH12022551618A1 (en) Programmed cell death receptor 1 antibody formulation and use thereof
WO2021050009A3 (en) Composition of renaturation buffer solution for dimeric proteins and method of renaturation dimeric proteins using the composition thereof
Shiraki et al. Amino acid esters prevent thermal inactivation and aggregation of lysozyme
CN108409852B (zh) 性激素结合球蛋白保存液以及其应用
MX2025010514A (es) Formulaciones de proteínas de alta concentración con excipientes de polisorbato y métodos para fabricarlas
AR128795A1 (es) FORMULACIÓN LIOFILIZADA QUE COMPRENDE UNA PROTEÍNA DE FUSIÓN QUE INCLUYE a-GALACTOSIDASA A
JOP20240024A1 (ar) صياغات الأجسام المضادة
JP2021521168A5 (enExample)
Huang et al. Protein covalent dimer formation induced by reversed‐phase HPLC conditions
PE20241936A1 (es) Formulaciones que comprenden fab-peg